Items where authors include "Brown, JR"

Article

Aggarwal, D, Page, AJ, Schaefer, U et al. (602 more authors) (2022) Genomic assessment of quarantine measures to prevent SARS-CoV-2 importation and transmission. Nature Communications, 13 (1). 1012.

Aggarwal, D, Warne, B, Jahun, AS et al. (725 more authors) (2022) Genomic epidemiology of SARS-CoV-2 in a UK university identifies dynamics of transmission. Nature Communications, 13 (1). 751. ISSN 2041-1723

Vöhringer, HS, Sanderson, T, Sinnott, M orcid.org/0000-0002-3054-7846 et al. (930 more authors) (2021) Genomic reconstruction of the SARS-CoV-2 epidemic in England. Nature, 600 (7889). pp. 506-511. ISSN 0028-0836

de Silva, TI orcid.org/0000-0002-6498-9212, Liu, G, Lindsey, BB orcid.org/0000-0003-4227-2592 et al. (1010 more authors) (2021) The impact of viral mutations on recognition by SARS-CoV-2 specific T cells. iScience, 24 (11). 103353. ISSN 2589-0042

Tam, CS, Robak, T, Ghia, P et al. (23 more authors) (2021) Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion. Haematologica, 106 (9). pp. 2354-2363. ISSN 0390-6078

Brown, JR, Brierley, CM, An, S-I et al. (23 more authors) (2020) Comparison of past and future simulations of ENSO in CMIP5/PMIP3 and CMIP6/PMIP4 models. Climate of the Past, 16 (5). pp. 1777-1805. ISSN 1814-9324

Munir, T, Brown, JR, O'Brien, S et al. (17 more authors) (2019) Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. American Journal of Hematology, 94 (12). pp. 1353-1363. ISSN 0361-8609

O'Brien, SM, Byrd, JC, Hillmen, P orcid.org/0000-0001-5617-4403 et al. (15 more authors) (2019) Outcomes with ibrutinib by line of therapy and post‐ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis. American Journal of Hematology, 94 (5). pp. 554-562. ISSN 0361-8609

Barrientos, JC, O'Brien, S, Brown, JR et al. (25 more authors) (2018) Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Clinical Lymphoma Myeloma and Leukemia, 18 (12). 803-813.e7. ISSN 2152-2650

Brown, JR, Hillmen, P orcid.org/0000-0001-5617-4403, O'Brien, S et al. (27 more authors) (2018) Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE(TM) study in patients with previously treated CLL/SLL. Leukemia, 32. pp. 83-91. ISSN 0887-6924

Brown, JR, Moslehi, J, O' Brien, S et al. (24 more authors) (2017) Characterization Of Atrial Fibrillation Adverse Events Reported In Ibrutinib Randomized Controlled Registration Trials. Haematologica, 102 (10). pp. 1796-1805. ISSN 0390-6078

Barr, PM, Brown, JR, Hillmen, P orcid.org/0000-0001-5617-4403 et al. (19 more authors) (2017) Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Blood, 129 (19). pp. 2612-2615. ISSN 0006-4971

Ryan, CE, Sahaf, B, Logan, AC et al. (13 more authors) (2016) Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. Blood, 128 (25). pp. 2899-2908. ISSN 0006-4971

Pugh, AC, Danise, S, Brown, JR et al. (1 more author) (2014) Benthic ecosystem dynamics following the Late Triassic mass extinction event: Palaeoecology of the blue lias formation, Lyme Regis, UK. Geoscience in South-West England, 13 (3). pp. 255-266. ISSN 0566-3954